文献速递消化道肿瘤与早癌消化内镜

基于实际依从性的结肠镜与粪便筛查对结直肠癌发病率与死亡率的预测

Projected Colorectal Cancer Incidence and Mortality Based on Observed Adherence to Colonoscopy and Sequential Stool-Based Screening.
PubMed 文献 · Am J Gastroenterol · 2024-02-06

研究利用MISCAN模型,基于美国结肠镜研究中的实际序贯依从性数据,比较每10年一次结肠镜筛查与每年高敏愈创木脂粪便隐血试验(HSgFOBT)对15年结直肠癌发病和死亡的影响。结果显示,在观察到的依从性下,结肠镜筛查的发病率和死亡率均低于HSgFOBT,尽管后者阳性后诊断性结肠镜依从性达91%。

要点

  • 实际依从性下,结肠镜筛查15年结直肠癌发病率和死亡率均低于HSgFOBT。
  • 结肠镜筛查依从性83.6%,HSgFOBT首轮73.1%但第四轮降至49.1%。
  • 结肠镜对比HSgFOBT的结直肠癌死亡相对风险为0.75(95%概率区间0.68-0.80)。

核心结论

  • 当粪便筛查序贯依从性不理想且结肠镜可及可接受时,结肠镜筛查在降低结直肠癌发病和死亡上优于HSgFOBT。

研究设计与样本

  • 基于美国结肠镜研究的微观模拟筛查分析(MISCAN)模型,比较无筛查、每10年结肠镜筛查与每年HSgFOBT在100%依从和实际观察依从下的15年效果。

主要发现

  • 无筛查时15年模拟发病率和死亡率分别为20.9(95%概率区间15.8-26.9)和6.9(5.0-9.2)/1000人。
  • 100%依从时仅结肠镜筛查降低发病率,两者死亡率相似(结肠镜2.1[1.6-2.9],HSgFOBT2.5[1.8-3.4])。
  • 实际依从下结肠镜筛查发病率和死亡率分别为14.4(10.8-18.5)和2.9(2.1-3.9)/1000人,低于HSgFOBT的20.8(15.8-28.1)和3.9(2.9-5.4)/1000人。
  • 结肠镜对比HSgFOBT的结直肠癌死亡相对风险为0.75(95%概率区间0.68-0.80)。

临床怎么用

  • 在推荐结直肠癌筛查时,应考虑实际序贯依从性对筛查效果的影响,结肠镜可及且依从性较高时可优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Modeling supporting recommendations for colonoscopy and stool-based colorectal cancer (CRC) screening tests assumes 100% sequential participant adherence. The impact of observed adherence on the long-term effectiveness of screening is unknown. We evaluated the effectiveness of a program of screening colonoscopy every 10 years vs annual high-sensitivity guaiac-based fecal occult blood testing (HSgFOBT) using observed sequential adherence data. METHODS: The MIcrosimulation SCreening ANalysis (MISCAN) model used observed sequential screening adherence, HSgFOBT positivity, and diagnostic colonoscopy adherence in HSgFOBT-positive individuals from the National Colonoscopy Study (single-screening colonoscopy vs ≥4 HSgFOBT sequential rounds). We compared CRC incidence and mortality over 15 years with no screening or 10 yearly screening colonoscopy vs annual HSgFOBT with 100% and differential observed adherence from the trial. RESULTS: Without screening, simulated incidence and mortality over 15 years were 20.9 (95% probability interval 15.8-26.9) and 6.9 (5.0-9.2) per 1,000 participants, respectively. In the case of 100% adherence, only screening colonoscopy was predicted to result in lower incidence; however, both tests lowered simulated mortality to a similar level (2.1 [1.6-2.9] for screening colonoscopy and 2.5 [1.8-3.4] for HSgFOBT). Observed adherence for screening colonoscopy (83.6%) was higher than observed sequential HSgFOBT adherence (73.1% first round; 49.1% by round 4), resulting in lower simulated incidence and mortality for screening colonoscopy (14.4 [10.8-18.5] and 2.9 [2.1-3.9], respectively) than HSgFOBT (20.8 [15.8-28.1] and 3.9 [2.9-5.4], respectively), despite a 91% adherence to diagnostic colonoscopy with FOBT positivity. The relative risk of CRC mortality for screening colonoscopy vs HSgFOBT was 0.75 (95% probability interval 0.68-0.80). Findings were similar in sensitivity analyses with alternative assumptions for repeat colonoscopy, test performance, risk, age, and projection horizon. DISCUSSION: Where sequential adherence to stool-based screening is suboptimal and colonoscopy is accessible and acceptable-as observed in the national colonoscopy study, microsimulation, comparative effectiveness, screening recommendations.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, et al. Projected Colorectal Cancer Incidence and Mortality Based on Observed Adherence to Colonoscopy and Sequential Stool-Based Screening. Am J Gastroenterol. 2024. PMID: 38318949. doi:10.14309/ajg.0000000000002693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。